Venture Life Group (VLG) investor relations material

Executive summary

• Revenue for the seventeen-month period ended 31 May 2026 reached £50.0 million, up 30.9% versus the prior period, with proforma growth of 16.0% driven mainly by volume increases.

• Adjusted EBITDA for the period is expected to be in line with market guidance, reflecting robust operational performance.

• Power Brands accounted for 91.2% of group revenues in the last five months, growing 20.7% to £13.4 million.

• The acquisition of FemiClear and CUROXEN was completed in June 2026, providing a strategic entry into the US market.

Financial highlights

• Group revenues grew 30.9% year-over-year to £50.0 million for the seventeen-month period.

• Adjusted Free Cash Flow for the period was approximately £5.9 million, up from £5.1 million in the previous twelve months.

• Net cash at 31 May 2026 was c. £12.0 million, reflecting the advance payment for the FemiClear and CUROXEN acquisition.

• Power Brands delivered 17.0% revenue growth for the period, with VLG Products up 19.0%.

Outlook and guidance

• Continued investment in Power Brands and innovation pipeline is planned, with a focus on marketing, data, and organizational resources.

• The Board remains optimistic about organic growth prospects and is actively exploring further earnings-enhancing M&A opportunities in the UK and US.

• The newly acquired US brands are performing in line with expectations and will be a bridgehead for further expansion.